Cargando…

Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo

Dysregulation of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling pathway is frequently observed in multiple human malignancies, and thus, therapeutic strategies targeting FGFs and FGFRs in human cancer are being extensively explored. We observed the activation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boichuk, Sergei, Galembikova, Aigul, Dunaev, Pavel, Micheeva, Ekaterina, Valeeva, Elena, Novikova, Maria, Khromova, Natalya, Kopnin, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222839/ https://www.ncbi.nlm.nih.gov/pubmed/30326595 http://dx.doi.org/10.3390/molecules23102643

Ejemplares similares

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
por: Boichuk, Sergei, et al.
Publicado: (2023)

Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib
por: Boichuk, Sergei, et al.
Publicado: (2020)

Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair
por: Boichuk, Sergei, et al.
Publicado: (2020)

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance
por: Boichuk, Sergei, et al.
Publicado: (2017)

Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline
por: Boichuk, Sergei, et al.
Publicado: (2023)

The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site
por: Boichuk, Sergei, et al.
Publicado: (2021)

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)

Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors
por: Sergei, Boichuk, et al.
Publicado: (2020)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines
por: Boichuk, Sergei, et al.
Publicado: (2021)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
por: Ghias, Adnan Asif Parvez, et al.
Publicado: (2018)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Divergent impact of actin isoforms on cell cycle regulation
por: Dugina, Vera, et al.
Publicado: (2018)

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
por: Deshaies, Isabelle, et al.
Publicado: (2010)

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018)

SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib
por: Chen, Yan, et al.
Publicado: (2022)

A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)
por: Cappello, Giovanni, et al.
Publicado: (2023)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Laparoscopic resection of locally advanced gastrointestinal stromal tumour (GIST) of the stomach following neoadjuvant imatinib chemoreduction
por: Berney, Christophe R.
Publicado: (2015)

Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib
por: Werewka-Maczuga, Agnieszka, et al.
Publicado: (2017)

Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
por: den Hollander, Dide, et al.
Publicado: (2022)

The radiology of gastrointestinal stromal tumours (GIST)
por: Michael King, D
Publicado: (2005)

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007)

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
por: Wu, Ting-Jung, et al.
Publicado: (2006)

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
por: Joensuu, H, et al.
Publicado: (2011)

Spontaneous Non-Traumatic Mediastinal Hematoma in a Patient on Imatinib Therapy for a Gastrointestinal Stromal Tumor (GIST)
por: Aziz, Rida, et al.
Publicado: (2023)

Tumor promotion by γ and suppression by β non-muscle actin isoforms
por: Dugina, Vera, et al.
Publicado: (2015)

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients
por: Bümming, P, et al.
Publicado: (2003)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy
por: Vassos, Nikolaos, et al.
Publicado: (2021)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
por: Vetto, John T
Publicado: (2009)

Computational-Based Discovery of the Anti-Cancer Activities of Pyrrole-Based Compounds Targeting the Colchicine-Binding Site of Tubulin
por: Boichuk, Sergei, et al.
Publicado: (2022)

Interaction of microtubules with the actin cytoskeleton via cross-talk of EB1-containing +TIPs and γ-actin in epithelial cells
por: Dugina, Vera, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1qus40fa9upsn35h9e9a6tdd9r